dosedrugsOnlineOfflineع
You're offline — running on data saved to your device.
phesgo 600mg/600mg/20.000 units s.c. sol. for inj. 10 ml
فيزجو 600مجم/600مجم/20.000وحدة 10 مل
pertuzumab+trastuzumab+hyaluronidase · 600mg + 600mg
104714EGP
Available
Active ingredient
pertuzumab+trastuzumab+hyaluronidase
Strength
600mg + 600mg
Form
syringe
Manufacturer
roche
Route
injection

Uses

Used with chemotherapy for HER2-positive early breast cancer and with docetaxel for HER2-positive metastatic breast cancer. It is indicated in selected patients as part of HER2-targeted therapy.

Do not use if

Hypersensitivity to pertuzumab, trastuzumab, hyaluronidase, or any component of the formulation.

Side effects

Common adverse effects include diarrhea, fatigue, nausea, alopecia, injection-site reactions, and neutropenia. Serious cardiac, pulmonary, and hypersensitivity reactions may occur.

Warnings

May cause cardiomyopathy, embryo-fetal toxicity, and pulmonary toxicity. Cardiac monitoring is required during treatment.

How it works

Pertuzumab and trastuzumab target different HER2 receptor domains and inhibit tumor cell signaling. Hyaluronidase facilitates subcutaneous administration.

Storage

Store refrigerated at 2°C to 8°C in the original carton. Do not freeze or shake.